drugset
Drugs / Palazestrant
last change Jun 2026 re-read 9 days ago

Palazestrant

also known as OP-1250

Small molecule

Developed for
estrogen-receptor positive breast cancer · Her2-receptor negative breast cancer · breast cancer · hormone receptor-positive breast cancer
Investigated by
Olema Pharmaceuticals, Inc. · Pfizer · Novartis · Novartis Pharmaceuticals

Trials 6

today NCT07085767 · Ph 3 NCT06784193 · Ph 1 NCT06016738 · Ph 3 NCT05508906 · Ph 1 NCT05266105 · Ph 1 NCT04505826 · Ph 1/2
202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT06784193 Dec 2024 → May 2027 expected castration-resistant prostate carcinoma, estrogen-receptor positive breast cancer, non-small cell lung carcinoma, progesterone-receptor positive breast cancer Olema Pharmaceuticals, Inc. Recruiting No outcome recorded
Phase 1 NCT05508906 Aug 2022 → Dec 2027 expected Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer Olema Pharmaceuticals, Inc. Active not recruiting No outcome recorded
Phase 1 NCT05266105 Dec 2021 → Mar 2026 overdue breast cancer Olema Pharmaceuticals, Inc. Active not recruiting No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT04505826 Aug 2020 → Jul 2024 hormone receptor-positive breast cancer Olema Pharmaceuticals, Inc. Completed No outcome recorded
Phase 32 trials
Phase 3 NCT07085767 Nov 2025 → Dec 2028 expected Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer Olema Pharmaceuticals, Inc. Recruiting No outcome recorded
Phase 3 NCT06016738 Nov 2023 → Jun 2026 overdue Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer Olema Pharmaceuticals, Inc. Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2026-04-17 Olema Pharmaceuticals, Inc. Results Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting olema.com ↗
Combining OP-3136 with palazestrant drives synergistic anti-tumor activity in in vivo ER+/HER2- breast cancer models, which is mediated by suppression of cell-cycle and estrogen receptor-driven oncogenic signaling processes.

All press releases naming this drug 2 releases

DateIssuerRelease

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Palazestrant ClinicalTrials.gov intervention name — accepted as the source's own label NCT06784193 ↗
4

NCT06016738 ↗

NCT07085767 ↗

NCT05266105 ↗

NCT05508906 ↗
Known as OP-1250 “Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation).” NCT05508906 ↗
1

NCT04505826 ↗
Action Inhibit “Complete Estrogen Receptor Antagonist” NCT05266105 ↗
Modality Small molecule — CHEMBL5314475 ↗
Route Oral “palazestrant administered orally (PO) daily” NCT05508906 ↗